Mitsubishi Chemical Medience Markets POCT Device To The U.S. And Canada
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based medical device maker Mitsubishi Chemical Medience began marketing compact automated immunoassay analyzer Pathfast to the U.S. and Canada. FDA approved the device along with N-Terminal proBNP (brain natriuretic peptide) testing as a marker of congestive heart failure. A point-of-care testing device, PATHFAST is used for night and emergency care testing and has been marketed in Europe and Korea. The company has signed distribution agreements with North American distributors and hopes to get six more test reagents approved by the FDA by this December. Mitsubishi Chemical estimates within three years that Pathfast will reach 10 percent of the BNP testing market with ¥4 billion in sales. (Click here for more - Japanese language